Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Hypotheses:
H1: Celecoxib, when given less than five days after injury will result in a statistical
decrease in the incidence and/or severity of radiographically apparent Heterotopic
Ossification when compared to controls.
H2a: A biomarker profile will accurately predict which patients in the treatment group will
respond to Celecoxib prophylaxis for Heterotopic Ossification.
H2b: A biomarker profile will accurately predict which patients in the control group are at
highest risk of developing Heterotopic Ossification